Pegylated Lipids for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as mRNA and oligonucleotides, face challenges including susceptibility to nuclease digestion in plasma and limited ability to access the intracellular compartment, leading to inefficient therapeutic delivery.
Innovation Solution
The development of pegylated lipid compounds that can form lipid nanoparticles in combination with other lipid components, such as cationic lipids and neutral lipids, to protect and deliver nucleic acids effectively both in vitro and in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free nucleic acids are administered, then they can be delivered to target cells, but they are susceptible to nuclease digestion in plasma and have limited ability to access the intracellular compartment
Solution Approach 1:
The patent uses composite lipid nanoparticles comprising multiple lipid components (cationic lipids, neutral lipids, cholesterol, and PEGylated lipids) to deliver nucleic acids. This composite structure provides both plasma stability through PEGylation and cellular uptake through cationic lipid-mediated endocytosis, resolving the contradiction between stability and cellular access.
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier that protects nucleic acids from plasma nucleases while facilitating cellular uptake. The PEGylated lipid component specifically mediates plasma stability by forming a protective steric barrier, while the cationic lipid component mediates cellular entry through electrostatic interactions with cell membranes.
2Reliability
If lipid nanoparticles are formed to protect nucleic acids from degradation, then stability in plasma is improved, but the ability to deliver nucleic acids intracellularly may be reduced
Solution Approach 1:
The lipid nanoparticle employs local quality differentiation where different lipid components perform specialized functions: PEGylated lipids provide plasma stability at the outer surface, while cationic lipids positioned within the particle structure provide intracellular delivery capability. This spatial differentiation of functions resolves the contradiction between protection and delivery efficiency.
Solution Approach 2:
The multi-component lipid formulation creates a composite material where each component contributes specific properties. The synergistic interaction between PEGylated lipids (protection) and cationic lipids (delivery) within the nanoparticle structure simultaneously achieves both plasma stability and efficient intracellular delivery.
3Reliability
If optimal drug-to-lipid ratios are provided for therapeutic efficacy, then the therapeutic index is improved, but the formulation complexity increases
Solution Approach 1:
The patent optimizes specific parameters including the PEG lipid content (0.5-5 mol%), cationic lipid content (10-40 mol%), and drug-to-lipid ratios to achieve optimal therapeutic index. By systematically adjusting these parameters within defined ranges, the formulation achieves efficacy while managing complexity through established optimization protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These lipid nanoparticles enhance the stability and intracellular delivery of nucleic acids, improving the therapeutic index by providing optimal drug-to-lipid ratios and ensuring well-tolerated systemic delivery.
Implementation Method 1
Lipid nanoparticles formed from components, such as cationic lipids, neutral lipids, cholesterol, PEG, PEGylated lipids, and oligonucleotides have been used to block degradation of the RNAs in plasma
Implementation Method 2
Lipid nanoparticles formed from components, such as cationic lipids, neutral lipids, cholesterol, PEG, PEGylated lipids, and oligonucleotides have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides
Data Source
AI summary
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein R1, R2, R3, m, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.